Areteia Therapeutics

About

Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease.

Bernardsville,New Jersey,United States
11 - 50
https://areteiatx.com

Highlights

Details

Last Funding Type: Series A
Last Funding Money Raised: $350M
Industries: Biotechnology,Health Care,Life Science,Therapeutics
Founded date: Jan 1, 2022
Number Of Employee: 11 - 50
Operating Status: Active

Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication of improving lung function and is found in several asthma-related treatments.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

1

$350M

Areteia Therapeutics has raised a total of $350M in funding over 2 rounds. Their latest funding was raised on Jul 12, 2022 from a Series A round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jul 12, 2022	Series A	$350M	8	Bain Capital Life Sciences	—	Detail

Investors

Number of Lead Investors

Number of Investors

1

8

Areteia Therapeutics is funded by 8 investors. Bain Capital Life Sciences and Sanofi are the most recent investors.

Investor Name	Lead Investor	Funding Round
Bain Capital Life Sciences	Yes	Series A
Sanofi	—	Series A
Access Biotechnology	—	Series A
ARCH Venture Partners	—	Series A
GV	—	Series A
Maverick Capital	—	Series A
Population Health Partners	—	Series A
Saturn Partners	—	Series A